Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Pasithea Therapeutics Corp
(NQ:
KTTA
)
4.551
-0.159 (-3.38%)
Streaming Delayed Price
Updated: 3:28 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pasithea Therapeutics Corp
< Previous
1
2
3
4
5
6
7
Next >
Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive
October 14, 2022
Via
Benzinga
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics
October 13, 2022
From
Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 12, 2022
Gainers
Via
Benzinga
EXCLUSIVE: Pasithea Bolsters CNS-Focused Pipeline With AlloMek Therapeutics Acquisition
October 12, 2022
Pasithea Therapeutics Corp (NASDAQ: KTTA) has acquired AlloMek Therapeutics LLC, a privately-held biotechnology company,
Via
Benzinga
New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope
October 10, 2022
People suffering from incurable neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) hope new therapies and drugs will arrive sooner than later.
Via
Benzinga
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
October 03, 2022
Learn More about Pasithea Therapeutics by gaining access to the latest research report
Via
TheNewswire.com
Pasithea Therapeutics Awarded A Drug Development Research Grant
July 14, 2022
-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction -- -- Provides approximately U.S. $694,000 of non-dilutive funding --
Via
Benzinga
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
October 12, 2022
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide...
Via
FinancialNewsMedia
Exposures
COVID-19
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
October 03, 2022
By Mark Gilman, Benzinga
Via
News Direct
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
October 03, 2022
Vaccines that boost the body’s immune system against foreign proteins are different than those that are an inverse vaccine fighting an autoimmune disease.
Via
Benzinga
Ron Bauer, Author of Exit Plan: How to Raise Money & Go Public, has a book release planned for December 2022
September 29, 2022
Via
Get News
Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors
September 28, 2022
From
Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC
Via
Business Wire
Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics
September 06, 2022
From
Camac Partners, LLC, Affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 31, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 30, 2022
Via
Benzinga
Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting
August 24, 2022
From
CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC
Via
Business Wire
EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With Potential In Monkeypox
August 11, 2022
Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced results from a preliminary preclinical proof of concept study of PAS002, its tolerizing vaccine for multiple sclerosis (MS).
Via
Benzinga
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
August 08, 2022
An estimated 200 million Americans — more than 60% of the population — suffer from at least one neurological disorder. That includes dementia, strokes, migraines and other diseases or infections that...
Via
Benzinga
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
August 11, 2022
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by...
Via
FinancialNewsMedia
Exposures
COVID-19
Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting
August 05, 2022
From
CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 02, 2022
Gainers Applied DNA Sciences (NASDAQ:APDN) stock rose 90.0% to $5.32 during Tuesday's after-market session. At the close, Applied DNA Sciences's trading volume reached 28.8 million shares. This is...
Via
Benzinga
A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea
July 28, 2022
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
July 22, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
July 20, 2022
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million.
Via
Benzinga
Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options
July 20, 2022
Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing.
Via
Benzinga
Pasithea Therapeutics Receives AUD $1 Million Research Award Following Recent Acquisition
July 18, 2022
Pasithea Therapeutics Corp. (NASDAQ: KTTA) recently announced the availability of an AUD $1 million (USD $694,000) drug development research award following the Company's acquisition of Alpha-5...
Via
Benzinga
This Biotech Company Says That It's Looking To Deliver A Breakthrough In Psychiatric Medicine — What's The Scoop?
June 27, 2022
Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotech company with a goal of investigating novel drug treatments to provide more effective relief to the estimated 792 million people around the world...
Via
Benzinga
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5
June 23, 2022
From
Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC
Via
Business Wire
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
June 22, 2022
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It...
Via
FinancialNewsMedia
EXCLUSIVE: Pasithea Expands Its Core Therapeutic Pipeline With This Acquisition
June 22, 2022
Pasithea Therapeutics Corp (NASDAQ: KTTA) has acquired Alpha-5 integrin LLC, a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for amyotrophic lateral sclerosis (ALS)...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.